Edgar Lomax Co. VA Sells 2,400 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Edgar Lomax Co. VA reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 125,590 shares of the biopharmaceutical company's stock after selling 2,400 shares during the quarter. Edgar Lomax Co. VA's holdings in Gilead Sciences were worth $11,601,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC grew its position in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new position in Gilead Sciences during the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences during the fourth quarter worth about $29,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC grew its stake in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the firm's stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the completion of the sale, the chief financial officer now directly owns 171,223 shares of the company's stock, valued at $17,502,415.06. This trade represents a 44.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 302,785 shares of company stock worth $30,540,875 over the last three months. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

NASDAQ:GILD traded up $0.44 during trading hours on Wednesday, hitting $105.95. 3,614,728 shares of the company traded hands, compared to its average volume of 7,496,961. The firm has a 50-day moving average of $109.17 and a 200 day moving average of $97.82. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $131.93 billion, a price-to-earnings ratio of 286.35, a P/E/G ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.98%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's dividend payout ratio is 854.05%.

Analyst Upgrades and Downgrades

GILD has been the topic of several research analyst reports. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research note on Tuesday. They set an "overweight" rating and a $125.00 target price on the stock. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Bank of America raised their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada lifted their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. Ten analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average price target of $106.92.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.